Replies to post #677638 on NorthWest Biotherapeutics Inc (NWBO)

[TTsr]

My opinion is your opinion is bought… the FDA will approve DCVax if they just approved a MAB with a CR of 42% and an AE profile of: “Serious toxicities occurred in 62% of patients, and 8% of patients experienced adverse reactions that proved to be fatal. Fatal toxicities included multiorgan failure, lung infection, sepsis, and encephalopathy. Moreover, 11% of patients required dose interruptions due to an adverse effect (AE) and 21% experienced an AE that led to permanent treatment discontinuation.”

https://www.onclive.com/view/fda-approves-inotuzumab-ozogamicin-for-pediatric-cd22-b-cell-precursor-acute-lymphoblastic-leukemia?ekey=RUtJRDpFRDZEQjY4OC1ENENFLTRENUQtODM3MC04MEFEQzFGNTYwMzk%3D&utm_medium=email&_hsmi=297454041&_hsenc=p2ANqtz--AyjNArMOOez1798jcI7rc9_auqoVqj4L_2dBKQ2Hmet_0y9JwT7d3pamlp7PilsKlFfCRn8FktvdfoHRwD3NKp5NntQ&utm_content=297454041&utm_source=hs_email